EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Discrepant CD3+ TILs in PD-L1–Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy

Mataichi Sekiya, Munehide Nakatsugawa, Nobuyuki Koyama iD, Naohiro Kajiwara, Takuya Aoki

American Journal of Case Reports · 2026

DOI: 10.12659/ajcr.951075 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Case Reports, 2026. Verfasst von Mataichi Sekiya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Hachioji City, Tokyo, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Nivolumab, Ipilimumab. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungNivolumabIpilimumabAntineoplastic Agents, ImmunologicalLymphocytes, Tumor-InfiltratingAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAged, 80 and overB7-H1 AntigenCD3 ComplexImmune Checkpoint Inhibitors

Substanzen

NivolumabIpilimumabAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD3 ComplexCD274 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Hachioji City, Tokyo, Japan.
  • Department of Diagnostic Pathology, Tokyo Medical University Hachioji Medical Center, Hachioji City, Tokyo, Japan.
  • Department of Thoracic Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji City, Tokyo, Japan.

ORCID-Profile: Nobuyuki Koyama

Zitieren

APA

Sekiya, M., Nakatsugawa, M., Koyama, N., Kajiwara, N., & Aoki, T. (2026). Discrepant CD3+ TILs in PD-L1–Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy. American Journal of Case Reports. https://doi.org/10.12659/ajcr.951075

Vancouver

Sekiya M, Nakatsugawa M, Koyama N, Kajiwara N, Aoki T. Discrepant CD3+ TILs in PD-L1–Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy. American Journal of Case Reports. 2026. doi:10.12659/ajcr.951075

BibTeX
@article{Sekiya2026,
  author = {Sekiya, Mataichi and Nakatsugawa, Munehide and Koyama, Nobuyuki and Kajiwara, Naohiro and Aoki, Takuya},
  title = {Discrepant CD3+ TILs in PD-L1–Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy},
  journal = {American Journal of Case Reports},
  year = {2026},
  doi = {10.12659/ajcr.951075}
}
Kostenlos starten →